Keywords: |
cancer survival; treatment response; survival analysis; cancer surgery; survival rate; clinical trial; bevacizumab; fluorouracil; cancer combination chemotherapy; multimodality cancer therapy; liver neoplasms; note; united states; disease free survival; chemotherapy, adjuvant; follow up; cancer immunotherapy; progression free survival; antimetabolites, antineoplastic; antineoplastic combined chemotherapy protocols; dexamethasone; practice guideline; continuous infusion; irinotecan; colorectal carcinoma; colorectal neoplasms; liver metastasis; folinic acid; infusions, intra-arterial; liver resection; cancer relapse; mitomycin; oxaliplatin; floxuridine; leucovorin; infusion; hepatic artery; infusion pump
|